351. Deputy Kevin O'Keeffe asked the Minister for Health if he will seek a review of the decision not to include a person (details supplied) in the reimbursement of costs of the drug Ocrevus who are suffering from the primary progressive multiple sclerosis; if his attention has been drawn to the fact that only relapsing or remitting patients were approved for reimbursement costs; and if his attention has been further drawn to the fact that the drug costs €7,000 per dose. [49841/19]

As this refers to an individual case, I have referred this matter to the HSE for their attention and direct reply to the Deputy.